Surgeon General: Federal drug classification needs changes

December 6, 2018 by Philip Marcelo

The nation's drug classification system should be revisited but illegal drugs shouldn't simply be decriminalized nationwide, U.S. Surgeon General Jerome Adams told a gathering of police leaders focused on the opioids crisis Thursday in Boston.

"Our scheduling system is functioning, but not as ideally as it could," he said of the federal schedule for controlled substances maintained by the Drug Enforcement Administration and the Food and Drug Administration. "Things aren't static. We have to continue to evolve."

Adams, who serves as the primary adviser on and scientific issues for U.S. Secretary of Health and Human Services Alex Azar, said one concern is that researchers are having difficulty studying the medial potential of marijuana because of the drug's classification.

The DEA considers marijuana a "Schedule I" drug along with heroin and LSD because it has no "currently accepted medical use and a high potential for abuse," according to its website.

"Just as we need to look at our criminal justice laws, we need to look at our health laws and regulations, and that includes the scheduling system," Adams said.

But Adams said he isn't supportive of "across-the-board" decriminalization of as some countries in Europe have tried.

"I don't think it's the federal government's place. I don't personally think it makes the country safer," he told the roughly 400 law enforcement officials from about 30 states in attendance.

He said the federal government should instead encourage local jurisdictions to develop drug policies that work for them.

"Local control and local innovation is what I'm all about," said Adams, who was appointed by President Donald Trump last year after serving as Indiana's State Health Commissioner under then-Governor Mike Pence, who is now Trump's vice president. "What works in Boston, Massachusetts, isn't going to work in Dallas, Texas and vice versa."

As the national opioid epidemic rages, Adams said his office is focused on addiction prevention and education efforts around prescription painkillers.

It's also pushing for expanded use of naloxone, an overdosing-reversal drug, among emergency responders and families dealing with substance abuse. His office issued a recent advisory stressing the importance of it close at hand and having the proper training to administer it.

The two-day summit at Harvard Medical School runs through Friday and is being hosted by the Police Assisted Addiction & Recovery Initiative.

The Massachusetts-based organization supports police efforts nationwide that are trying to get more people struggling with addiction into treatment programs.

Explore further: US surgeon general urges Americans to carry opioid antidote

Related Stories

US surgeon general urges Americans to carry opioid antidote

April 5, 2018
The top US doctor on Thursday urged more Americans to carry naloxone, an antidote to opioid overdose, as the nation grapples with a surge in deaths due to potent prescription painkillers and heroin.

Feds say heroin, fentanyl remain biggest drug threat to US

November 2, 2018
Opioid overdose deaths hit the highest level ever recorded in the United States last year, with an estimated 200 people dying per day, according to a report by the U.S. Drug Enforcement Administration.

New US survey shows some progress against opioid crisis

September 14, 2018
Figures from a U.S. government survey released Friday show some progress in the fight against the ongoing opioid addiction crisis with fewer people in 2017 using heroin for the first time compared to the previous year.

Trump declares opioid crisis a 'national emergency'

August 11, 2017
US President Donald Trump said Thursday that the opioid crisis in the United States constitutes a "national emergency" and pledged to step up efforts to fight the epidemic.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Trump administration toughens stance on recreational marijuana (Update)

January 4, 2018
The US Justice Department on Thursday reversed official policy that had tolerated the growing state-based movement to legalize marijuana sales, just three days after California formally permitted recreational use of the drug.

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.